跳至主要内容
临床试验/NCT00348400
NCT00348400已完成4 期

Brimonidine Purite 0.15% Versus Dorzolamide 2% Used as Adjunctive Therapy to Latanoprost

Innovative Medical1 个研究点 分布在 1 个国家开始时间: 2006年7月4日最近更新:
适应症
相关药物

试验速览

阶段
4 期
状态
已完成
试验地点
1

研究概览

简要总结

Evaluate the relative efficacy and tolerability of Alphagan P compared to Trusopt as adjunctive therapy

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
盲法
Single

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者
否

入选标准

  • •· Male or female > 18 years of age
  • •Diagnosis of open-angle glaucoma or ocular hypertension
  • •IOP > 16 mm Hg in each eye at the latanoprost -treated baseline evaluation
  • •Presently on latanoprost monotherapy for at least 6 weeks
  • •Ability to provide informed consent and likely to complete all study visits

排除标准

  • •· Known contraindication or allergy to brimonidine or any of its components
  • •Subjects must be naive to brimonidine 0.2% or brimonidine Purite 0.15% and dorzolamide 2%
  • •Uncontrolled systemic disease
  • •Active ocular disease other than glaucoma or ocular hypertension (e.g. uveitis, ocular infections, or severe dry eye). Patients with chronic mild blepharitis, cataract, age-related macular degeneration, or background diabetic retinopathy may be enrolled at the discretion of the investigator.
  • •Required use of ocular medications other than the study medications during the study (intermittent use of artificial tear product is allowed).
  • •Corneal abnormalities
  • •History of intraocular surgery within the last 3 months
  • •Female patients of childbearing potential who are pregnant, lactating, planning a pregnancy, or not using a reliable form of birth control
  • •Visual field loss, which in the opinion of the investigator, is functionally significant, or evidence of progressive visual field loss within the last year.

研究者

申办方类型
Industry

研究点 (1)

Loading locations...

相似试验